Central Nervous System

Central Nervous System Resource Center

Welcome to the MPR Central Nervous System Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

FEATURE ARTICLE

Addressing the Treatment Challenges of Depression in Pregnancy

Kelly Bilodeau and Sheila M. Marcus, MD

An estimated 13% of women suffer from depression during or after pregnancy, and treating the condition can be a challenge. Treatment decisions are getting even more complex since recent studies raised issues with the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. Sheila M. Marcus, MD, the co-director of the Women Mental Health and Infants Program at the University of Michigan in Ann Arbor, discusses how to evaluate risk and make prescribing decisions for expectant mothers.

News from APA 2012

Data Shows Patients Can be Safely and Effectively Switched to Latuda from Other Antipsychotics

Sunovion announced results from an open-label study showing that clinically stable, but symptomatic adult outpatients with schizophrenia can be effectively switched from other antipsychotic agents to Latuda (lurasidone).

Study Shows Lu AA21004 to be Effective in Elderly for Major Depressive Disorder

Lundbeck and Takeda announced that Lu AA21004, an investigational compound for the treatment of major depressive disorder (MDD), demonstrated significant improvements in overall symptoms of depression in elderly patients.

Study Supports Gender-Specific Dosing of Intermezzo for Insomnia

Purdue presented data from a double-blind, placebo-controlled, cross-over pharmacokinetic study in healthy volunteers of Intermezzo (zolpidem tartrate sublingual tablets) in doses of 1mg, 1.75mg, and 3.5mg.

Deplin Medical Food Provides Long-Term Benefit for Major Depressive Disorder

Pamlab reported that new data from two studies affirm the long-term value of Deplin (L-methylfolate), a medical food, for the nutritional management of metabolic imbalance in patients with major depressive disorder (MDD).

Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

Phase 3 Trial Update of Latuda for Bipolar I Depression

Dainippon Sumitomo Pharma announced results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of Latuda (lurasidone; Sunovion) as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

Data Demonstrates Long-Term Prevention of Major Depressive Disorder Relapse with Pristiq

Pfizer announced that data from a long-term relapse prevention study shows that adult patients receiving Pristiq (desvenlafaxine extended-release tablets) 50mg/day experienced statistically significant longer time to relapse over six months compared with placebo.

News

IMFAR: Genetic Variants Predict Autism Risk in Siblings

For siblings of children with autism, a gender-specific genetic score based on single nucleotide polymorphisms (SNPs) in genes with biological and functional relevance to autism can predict the risk of developing an autism spectrum disorder (ASD).

SNCA Variants Linked to Motor Function Decline in Parkinson's

Variants of the alpha-synuclein gene (SNCA) are associated with a higher risk of a more rapid decline in motor function in patients with Parkinson's disease.

Leukoencephalopathy Risk Factors ID'd for MS Drug

Multiple sclerosis patients taking natalizumab are at higher risk of developing progressive multifocal leukoencephalopathy (PML) if they are positive for the anti-JC virus antibodies, have been treated with immunosuppressants, and have been treated with natalizumab for longer periods.